Skip to main content
SpringerLink
Log in

Combination Drug Therapy in the Elderly

  • Chapter
Hypertension in the Elderly

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

Abstract

Awareness, treatment, and control of hypertension in the United States have been improving for geriatric patients (1). However, awareness, treatment, and control remain the lowest among the oldest age group (2). This is ironic given the fact that the largest body of outcomes trials documents the reduction of morbidity and mortality in the elderly population. These trials are reviewed in detail in Chapter 7.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003;290:199–206.

    Article  PubMed  Google Scholar 

  2. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479–486.

    Article  PubMed  CAS  Google Scholar 

  3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.

    Article  PubMed  CAS  Google Scholar 

  4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  5. Prisant LM. Fixed low-dose combination therapy: current recommendations. Manag Care 2003;12(8 suppl Hypertension):45–50.

    PubMed  Google Scholar 

  6. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med 1994;154:1430–1431.

    Article  PubMed  CAS  Google Scholar 

  7. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914–921.

    Article  PubMed  CAS  Google Scholar 

  8. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189–192.

    Article  PubMed  CAS  Google Scholar 

  9. Ruzicka M, Leenen FH. Monotherapy vs combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001;61:943–954.

    Article  PubMed  CAS  Google Scholar 

  10. Brunner HR, Ménard J, Waeber B, et al. Treating the individual patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990;8:3–11.

    Article  PubMed  CAS  Google Scholar 

  11. Mancia G, Failla M, Grappiolo A, Giannattasio C. Present and future role of combination treatment in hypertension. J Cardiovasc Pharmacol 1998;31(suppl 2):S41–S44.

    Article  PubMed  CAS  Google Scholar 

  12. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001;37:12–18.

    PubMed  CAS  Google Scholar 

  13. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073–2082.

    Article  PubMed  CAS  Google Scholar 

  14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393–404.

    Article  Google Scholar 

  15. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.

    Google Scholar 

  16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805–2816.

    Article  PubMed  CAS  Google Scholar 

  17. Kaplan NM. Implications for cost-effectiveness. Combination therapy for systemic hypertension. Am J Cardiol 1995;76:595–597.

    Article  PubMed  CAS  Google Scholar 

  18. Fenichel RR, Lipicky RJ. Combination products as first-line pharmacotherapy. Arch Intern Med 1994;154:1429–1430.

    Article  PubMed  CAS  Google Scholar 

  19. Fenichel RR, Lipicky RJ. Combination products as first-line pharmacotherapy. Arch Intern Med 1995;155:117.

    Article  PubMed  CAS  Google Scholar 

  20. Prisant LM, Doll NC. Hypertension: the rediscovery of combination therapy. Geriatrics 1997;52:28–30, 33–38.

    PubMed  CAS  Google Scholar 

  21. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.

    Google Scholar 

  23. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033–1041.

    Google Scholar 

  24. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443–462.

    Article  PubMed  CAS  Google Scholar 

  25. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens 1987;3:278–293.

    PubMed  CAS  Google Scholar 

  26. Elliott HL, Meredith PA, Reid JL. Verapamil and prazosin in essential hypertension: evidence of a synergistic combination? J Cardiovasc Pharmacol 1987; 10(suppl10):S108–S110.

    PubMed  Google Scholar 

  27. Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994;154:1461–1468.

    Article  PubMed  CAS  Google Scholar 

  28. Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35:182–188.

    PubMed  CAS  Google Scholar 

  29. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–366.

    Article  PubMed  CAS  Google Scholar 

  30. Neutel JM, Rolf CN, Valentine SN, Li J, Lucas C, Marmorstein BL. Low-dose combination therapy as first line treatment of mild-to-moderate hypertension: the efficacy and safety of bisoprolol/HCTZ vs amlodipine, enalapril, and placebo. Cardiovasc Rev Rep 1996;17:33–45.

    Google Scholar 

  31. Morgan TO, Anderson A, Jones E. Comparison and interaction of low dose felodipine and enalapril in the treatment of essential hypertension in elderly subjects. Am J Hypertens 1992;5:238–243.

    PubMed  CAS  Google Scholar 

  32. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/ calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  33. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707–1713.

    Article  PubMed  CAS  Google Scholar 

  34. Prisant LM, Mensah GA. Use of β-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996;36:867–873.

    PubMed  CAS  Google Scholar 

  35. Prisant LM. Meet the experts: effective use of combination drug therapy in the treatment of minority hypertensive populations. Combination Therapy: Rediscovered. Ethn Dis 1997;7:165–168.

    PubMed  CAS  Google Scholar 

  36. Prisant LM, Neutel JM, Ferdinand K, et al. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc 1999;91:40–48.

    PubMed  CAS  Google Scholar 

  37. Vidt DG. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. J Hypertens Suppl 1984;2:S81–S88.

    Article  PubMed  CAS  Google Scholar 

  38. MacGregor GA, Markandu ND, Smith SJ, Sagnella GA. Captopril: contrasting effects of adding hydrochlorothiazide, propranolol, or nifedipine. J Cardiovasc Pharmacol 1985;7(suppl 1):S82–S87.

    PubMed  Google Scholar 

  39. Cheng A, Frishman WH. Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. J Clin Pharmacol 1998;38:477–491.

    PubMed  CAS  Google Scholar 

  40. Sutton JM, Bagby SP. Nontraditional combination pharmacotherapy of hypertension. Cleve Clin J Med 1992;59:459–468.

    PubMed  CAS  Google Scholar 

  41. Sica DA, Elliott WJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in combination: theory and practice. J Clin Hypertens (Greenwich) 2001;3:383–387.

    Article  CAS  Google Scholar 

  42. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–677.

    Article  PubMed  CAS  Google Scholar 

  43. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821–828.

    Google Scholar 

  44. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet 1994;343:1115–1122.

    Google Scholar 

  45. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669–685.

    Google Scholar 

  46. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80–85.

    Article  PubMed  CAS  Google Scholar 

  47. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670–1676.

    Article  PubMed  CAS  Google Scholar 

  48. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788.

    Article  PubMed  CAS  Google Scholar 

  49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet1999;353:2001–2007.

    Google Scholar 

  50. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353:9–13.

    Google Scholar 

  51. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  52. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–124.

    Article  PubMed  CAS  Google Scholar 

  53. Lenz ML, Pool JL, Laddu AR, Varghese A, Johnston W, Taylor AA. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens 1995;8:133–145.

    Article  PubMed  CAS  Google Scholar 

  54. Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000;13:921–926.

    Article  PubMed  CAS  Google Scholar 

  55. Kaesemeyer WH, Carr AA, Bottini PB, Prisant LM. Verapamil and nifedipine in combination for the treatment of hypertension. J Clin Pharmacol 1994;34:48–51.

    PubMed  CAS  Google Scholar 

  56. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996;28:109–114.

    PubMed  CAS  Google Scholar 

  57. Severs PS, Poulter NR. Calcium antagonists and diuretics as combined therapy. J Hypertens 1987;5(suppl 4):S123–S126.

    Article  Google Scholar 

  58. Frishman WH, Landau A, Cretkovic A. Combination drug therapy with calcium-channel blockers in the treatment of systemic hypertension. J Clin Pharmacol 1993;33:752–755.

    PubMed  CAS  Google Scholar 

  59. Nicholson JP, Resnick LM, Laragh JH. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Arch Intern Med 1989; 149:125–128.

    Article  PubMed  CAS  Google Scholar 

  60. Prisant LM, Carr AA, Nelson EB, Winer N, Velasquez MT, Gonasun LM. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation. Arch Intern Med 1989;149:2453–2457.

    Article  PubMed  CAS  Google Scholar 

  61. Letzel H, Bluemner E. Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial. J Hypertens Suppl 1990;8:S83–S86.

    PubMed  CAS  Google Scholar 

  62. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA 1990;263:1507–1512.

    Article  PubMed  CAS  Google Scholar 

  63. Prisant LM. Ambulatory blood pressure profiles in patients treated with once-daily diltiazem extended-release or indapamide alone or in combination. Am J Ther 2000;7:177–184.

    PubMed  CAS  Google Scholar 

  64. Martin BJ, Milligan K. Diuretic-associated hypomagnesemia in the elderly. Arch Intern Med 1987;147:1768–1771.

    Article  PubMed  CAS  Google Scholar 

  65. Petri M, Cumber P, Grimes L, et al. The metabolic effects of thiazide therapy in the elderly: a population study. Age Ageing 1986;15:151–155.

    Article  PubMed  CAS  Google Scholar 

  66. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025–1030.

    PubMed  CAS  Google Scholar 

  67. Myers MG. Hydrochlorothiazide with or without amiloride for hypertension in the elderly. A dose-titration study. Arch Intern Med 1987; 147:1026–1030.

    Article  PubMed  CAS  Google Scholar 

  68. Vanpee D, Swine CH. Elderly heart failure patients with drug-induced serious hyperkalemia. Aging (Milano) 2000; 12:315–319.

    CAS  Google Scholar 

  69. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438–441.

    Article  PubMed  CAS  Google Scholar 

  70. Prisant LM. Should β-blockers be used in the treatment of hypertension in the elderly? J Clin Hypertens (Greenwich) 2002;4:286–294.

    Article  CAS  Google Scholar 

  71. Dahlöf B, Lindholm LH, Hansson L, Scherstën B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hyper-tension). Lancet 1991;338:1281–1285.

    Article  PubMed  Google Scholar 

  72. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101: 71S–82S.

    Article  PubMed  CAS  Google Scholar 

  73. Neutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med 1996; 101:61S–70S.

    Article  PubMed  CAS  Google Scholar 

  74. Avanzini F, Alli C, Bettelli G, et al. Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly. Eur Heart J 1994;15:206–212.

    PubMed  CAS  Google Scholar 

  75. Tognoni G, Alli C, Avanzini F, et al. Randomised clinical trials in general practice: lessons from a failure. BMJ 1991;303:969–971.

    PubMed  CAS  Google Scholar 

  76. Benetos A, Consoli S, Safavian A, Dubanchet A, Safar M. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide vs amlodipine in elderly patients with systolic hypertension. Am Heart J 2000;140:E11.

    Article  PubMed  CAS  Google Scholar 

  77. McLay JS, MacDonald TM, Hosie J, Elliott HL. The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients. Eur J Clin Pharmacol 2000;56:529–535.

    Article  PubMed  CAS  Google Scholar 

  78. Wing LM, Russell AE, Tonkin AL, Bune AJ, West MJ, Chalmers JP. Felodipine, metoprolol and their combination compared with placebo in isolated systolic hypertension in the elderly. Blood Press 1994;3:82–89.

    PubMed  CAS  Google Scholar 

  79. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994;154:737–743.

    Article  PubMed  CAS  Google Scholar 

  80. Israili ZH, Hall WD. ACE inhibitors. Differential use in elderly patients with hypertension. Drugs Aging 1995;7:355–371.

    Article  PubMed  CAS  Google Scholar 

  81. Tuck ML, Katz LA, Kirkendall WM, Koeppe PR, Ruoff GE, Sapir DG. Low-dose captopril in mild to moderate geriatric hypertension. J Am Geriatr Soc 1986;34: 693–696.

    PubMed  CAS  Google Scholar 

  82. Hart W. Lisinopril-hydrochlorothiazide combination compared with the monocomponents in elderly hypertensive patients. J Hum Hypertens 1991;5(suppl 2):85–89.

    PubMed  Google Scholar 

  83. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000;18:327–337.

    Article  PubMed  CAS  Google Scholar 

  84. Castaigne A, Chalmers J, Morgan T, Chastang C, Feldmann L, Guez D. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens 1999;21:1097–1110.

    PubMed  CAS  Google Scholar 

  85. Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril vs atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003;16(5 pt 1):381–386.

    Article  PubMed  CAS  Google Scholar 

  86. Wing LM, Russell AE, Tonkin AL, et al. Mono-and combination therapy with felodipine or enalapril in elderly patients with systolic hypertension. Blood Press 1994;3:90–96.

    PubMed  CAS  Google Scholar 

  87. Chan P, Lin CN, Tomlinson B, Lin TH, Lee YS. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997;10(7 pt 1):743–749.

    Article  PubMed  CAS  Google Scholar 

  88. Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213–1224.

    Article  PubMed  CAS  Google Scholar 

  89. Holzgreve H, Compagnone D, Zilles P. Verapamil SR/trandolapril combination therapy for the elderly hypertensive patient. German VeraTran Hypertension Study Group. J Hum Hypertens 1999;13:61–67.

    Article  PubMed  CAS  Google Scholar 

  90. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  91. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.

    Article  PubMed  CAS  Google Scholar 

  92. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.

    Article  PubMed  CAS  Google Scholar 

  93. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  94. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–781.

    Article  PubMed  CAS  Google Scholar 

  95. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.

    Article  PubMed  CAS  Google Scholar 

  96. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767–771.

    Article  PubMed  CAS  Google Scholar 

  97. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–766.

    Article  PubMed  CAS  Google Scholar 

  98. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.

    Article  PubMed  CAS  Google Scholar 

  99. Critchley JAJH, Gilchrist N, Ikeda L, et al. A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide vs captopril and hydrochlorothiazide in elderly and younger patients. Curr Ther Res 1996;57:392–407.

    Article  CAS  Google Scholar 

  100. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003;suppl 1:36–43.

    Article  CAS  Google Scholar 

  101. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544–549.

    Article  PubMed  CAS  Google Scholar 

  102. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265: 3255–3264.

    Google Scholar 

  103. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757–764.

    Article  PubMed  CAS  Google Scholar 

  104. Wing LM, Arnolda LF, Harvey PJ, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. J Hypertens 1997; 15(12 pt 1):1503–1510.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Clinical Pharmacology, Department of Medicine, Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD, FACC, FACP

  2. Section of Nephrology, Hypertension, and Transplantation, Department of Medicine, Medical College of Georgia, Augusta, GA

    Laura Lyngby Mulloy DO, FACP

Authors
  1. L. Michael Prisant MD, FACC, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Lyngby Mulloy DO, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical College of Georgia, Augusta, GA

    L. Michael Prisant MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Prisant, L.M., Mulloy, L.L. (2005). Combination Drug Therapy in the Elderly. In: Prisant, L.M. (eds) Hypertension in the Elderly. Clinical Hypertension and Vascular Diseases. Humana Press. https://doi.org/10.1007/978-1-59259-911-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-911-0_20

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-197-4

  • Online ISBN: 978-1-59259-911-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation